Genmab A/S (OTCMKTS:GNMSF) and Processa Pharmaceuticals (OTCMKTS:PCSA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.
This table compares Genmab A/S and Processa Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Genmab A/S and Processa Pharmaceuticals’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Genmab A/S||$359.31 million||35.09||$167.62 million||N/A||N/A|
|Processa Pharmaceuticals||N/A||N/A||-$3.77 million||N/A||N/A|
Genmab A/S has higher revenue and earnings than Processa Pharmaceuticals.
Risk and Volatility
Genmab A/S has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Comparatively, Processa Pharmaceuticals has a beta of -0.43, meaning that its share price is 143% less volatile than the S&P 500.
This is a breakdown of current recommendations and price targets for Genmab A/S and Processa Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Institutional and Insider Ownership
0.1% of Genmab A/S shares are held by institutional investors. 49.7% of Processa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Genmab A/S beats Processa Pharmaceuticals on 7 of the 8 factors compared between the two stocks.
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
About Processa Pharmaceuticals
Processa Pharmaceuticals, Inc., a pharmaceutical company, engages in the clinical development of drug products for the unmet medical needs. Its lead product candidate is PCS-499, an oral tablet for the treatment of necrobiosis lipoidica and radiation-induced fibrosis in head and neck cancer patients. The company is based in Hanover, Maryland.
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.